Original Title: 흡입용 기관지확장제 및 스테로이드 사용에 따른 합병증에 대한 성과연구

Authors' recommendations: In ICS users, the risk of pneumonia was higher in MDI compared with DPI after adjustment for age, gender, respiratory disease, comorbidities, health care utilization, and concomitant medications (HR 1.6; 95% CI 1.2 to 2). Additionally, in ICS/LABA users, the risk of pneumonia was higher in MDI compared with DPI, after adjustment for age, gender, respiratory disease, comorbidities, health care utilization, and concomitant medications (HR 1.6; 95% CI 1.3 to 1.9). SABA was associated with a higher risk of hemoptysis (OR 1.2; 95% CI 1.2 to 1.4) after adjustment for other inhaler medication and age, Charlson comorbidity index (CCI), comorbidities, health care utilization, and concomitant medications. This association was observed in LAMA (OR 1.2; 95% CI 1.1 to 1.4) and SAMA (OR 1.6; 95% CI 1.1 to 2.4). After adjusting for concomitant medications, baseline characteristics, health care utilization, and medication history, the risk of PIH was lower for 0~15,000 mg ICS cumulative dose compared with non-users (OR 0.8; 95% CI 0.64 to 0.99). In contrast, the risk of PIH was higher in those receiving >15,000 mg compared with non-user (OR 1.3; 95% CI 1.01 to 1.79). SABA was associated with a higher risk of acute myocardial infarction (OR 1.2; 95% CI 1.1 to 1.3), after adjustment for other inhaler medication and age, CCI, comorbidities, health care utilization, and concomitant medications. This association was observed in LABA (OR 1.3; 95% CI 1.1 to 1.6). After adjusting for other inhaler medication and age, CCI, comorbidities, health care utilization, and concomitant medications, the risk of tachyarrhythmia was higher in ICS with LABA users compared with non-users (OR 1.2; 95% CI 1.0 to 1.3). This association was observed in LABA (OR 1.3; 95% CI 1.1 to 1.5). We suggest that the use of MDI device may increase the risk of hospital admission or emergency room visit for pneumonia than DPI device when ICS or ICS/LABA is used. SABA, LAMA, and SAMA may increase the risk of hemoptysis in bronchiectasis patients. As MPR or cumulative dose of ICS is higher, the risk of the PIH in pregnant women is higher. SABA, LABA or LABA alone may increase the risk of AMI and ICS/LABA or LAMA is associated with an increased risk of tachyarrhythmia.

Project Status: Completed

Year Published: 2014

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=95

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)